AVITA Medical, Inc. Stock

Equities

RCEL

US05380C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-14 pm EDT 5-day change 1st Jan Change
8.72 USD +4.43% Intraday chart for AVITA Medical, Inc. -6.94% -36.44%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 114M 75.66M Sales 2025 * 159M 106M Capitalization 340M 226M
Net income 2024 * -69M -45.83M Net income 2025 * -24M -15.94M EV / Sales 2024 * 2.76 x
Net cash position 2024 * 25.09M 16.66M Net cash position 2025 * 16.6M 11.03M EV / Sales 2025 * 2.03 x
P/E ratio 2024 *
-4.97 x
P/E ratio 2025 *
-26.6 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.3%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.43%
1 week-6.94%
Current month+3.81%
1 month-11.74%
3 months-49.65%
6 months-35.07%
Current year-36.44%
More quotes
1 week
7.51
Extreme 7.51
9.03
1 month
7.51
Extreme 7.51
10.20
Current year
7.51
Extreme 7.51
18.93
1 year
7.51
Extreme 7.51
21.70
3 years
4.41
Extreme 4.4102
22.49
5 years
4.41
Extreme 4.4102
55.35
10 years
3.75
Extreme 3.75
55.35
More quotes
Date Price Change Volume
24-05-14 8.72 +4.43% 508,967
24-05-13 8.35 +1.09% 239,554
24-05-10 8.26 -5.17% 329,508
24-05-09 8.71 -2.79% 368,469
24-05-08 8.96 -4.38% 371,776

Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.17 AUD
Average target price
35.32 AUD
Spread / Average Target
+168.23%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW